Creative Capital Management Investments’s ADMA Biologics ADMA Stock Holding History

Creative Capital Management Investments’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$176	Buy	+21	New	+$191	﹤0.01%	1398

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Creative Capital Management Investments's ADMA Position: Q2 2026 in Review

Creative Capital Management Investments opened a new position in ADMA Biologics (ADMA) in Q2 2026: 21 shares worth $176. The stake represents ﹤0.01% of the portfolio and ranks #1398 among its holdings.

322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Creative Capital Management Investments held 21 shares of ADMA Biologics worth $176 as of Q2 2026.
ADMA Biologics was a new Creative Capital Management Investments position in Q2 2026.
ADMA Biologics made up ﹤0.01% of Creative Capital Management Investments's portfolio in Q2 2026, its #1398 holding.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Creative Capital Management Investments's 13F filing for Q2 2026, filed 24 Jul 2026.